Immutep Ltd.’s stock on Australia’s Securities Exchange plummeted nearly 90% on March 13 on the news that its phase III TACTI-004 trial evaluating eftilagimod alfa (IMP-321, efti) in first-line non-small-cell lung cancer was discontinued due to futility.
Enodia Therapeutics SAS has acquired Kezar Life Sciences Inc.’s assets from its Sec61-based discovery and development program, including clinical-stage KZR-261. Insights from Kezar’s Sec61-based programs will further strengthen Enodia’s core focus on Sec61-driven selectivity for targeting protein degradation.
The Council of Scientific and Industrial Research has patented hybrid peptides acting as apoptosis inducer and reactive oxygen species (ROS) production enhancers designed for use in the treatment of cancer.
U.K. biopharma is working with the country’s space agency and Civil Aviation Authority (CAA) to plot a route for manufacturing biologic drugs in low earth orbit.
Zhejiang Pantheon Innovation Pharmaceutical Co. Ltd. has disclosed prodrugs of an NLRP3 inflammasome inhibitor compound. They are reported to be useful for the treatment of cancer and inflammation.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have discovered GTPase KRAS mutant inhibitors, particularly G12V, G12D and G12C mutant inhibitors. They are reported to be useful for the treatment of cancer.
Children’s Medical Center Corp. has synthesized ceramide glucosyltransferase (glucosylceramide synthase; GLCT-1) inhibitors with potential for use in the treatment of cancer, neurological disorders, infections and more.
RSS
